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Abstract 
 
MYH9-related disease (MYH9-RD) is a rare autosomal dominant syndromic disorder caused by 
mutations in MYH9, the gene encoding for the heavy chain of non-muscle myosin IIA (myosin-9). 
MYH9-RD is characterized by congenital macrothrombocytopenia and typical inclusion bodies in 
neutrophils associated with a variable risk of developing sensorineural deafness, presenile cataract, 
and/or progressive nephropathy. The spectrum of mutations responsible for MYH9-RD is limited. 
We report five families, each with a novel MYH9 mutation. Two mutations, p.Val34Gly and 
p.Arg702Ser, affect the motor domain of myosin-9, whereas the other three, p.Met847_Glu853dup, 
p.Lys1048_Glu1054del, and p.Asp1447Tyr, hit the coiled-coil tail domain of the protein. The 
motor domain mutations were associated with more severe clinical phenotypes than those in the tail 
domain. 
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INTRODUCTION 
 
MYH9-related disease (MYH9-RD) is an autosomal-dominant disorder characterized by 
thrombocytopenia, giant platelets and inclusion bodies in neutrophils deriving from the aggregation 
of mutant and wild type proteins [1-3]. In addition to the hematological features, patients can 
develop, during infancy or adult life, sensorineural hearing loss, presenile cataract and/or 
proteinuric nephropathy that often leads to end-stage renal disease [4, 5]. 
MYH9-RD is caused by mutations of MYH9, the gene encoding for the heavy chain (myosin-9) of 
the isoform A of the non-muscle myosin of class II [6, 7]. Class II myosins are hexameric 
complexes consisting of two heavy chains and two pairs of light chains. Each heavy chain contains 
a N-terminal globular head or motor domain, a long alpha-helix coiled-coil tail domain, and a short 
C-terminal non-helical tailpiece. The spectrum of mutations identified in the MYH9 gene is limited, 
consisting of 44 different alterations, mainly amino acids substitutions, hitting only 35 of the 1960 
residues of myosin-9. In fact, residues Ser96 or Arg702 of the globular head, and Arg1165, 
Asp1424, or Glu1841 of the coiled coil domain, or Arg1933 of the non-helical tailpiece are mutated 
in 79% of the reported families. The remaining alterations are private or detected in a few cases [2]. 
Genotype/phenotype studies have been reported showing that individuals with mutations in the 
motor domain of myosin-9 have more severe thrombocytopenia and higher risk of developing 
nephropathy and deafness [8-10]. Conversely, mutations in the tail domain are associated with a 
milder phenotype characterized by slight to moderate thrombocytopenia and a lower prevalence of 
extra-haematological manifestations. 
In this paper, we report the identification of five novel mutations, three missense variations in exons 
1, 16, and 30, and two in frame alterations of exons 20 and 24, thus extending the spectrum of 
mutations associated with MYH9-RD. The patients from these pedigrees presented with phenotypes 
consistent with the results of previous genotype/phenotype studies. 
 
PATIENTS AND METHODS 
 
Patients 
 
Family 1. The proband (II-1; Table 1 and Fig. 1) was an 11-year-old boy referred for diagnostic 
investigation of familial thrombocytopenia. Since his mother had reduced platelet count he 
previously received a diagnosis of Bernard-Soulier syndrome. His platelet count was 60 x109/L 
without bleeding history. Examination of peripheral blood smears after conventional staining 
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demonstrated giant platelets and Döhle-like basophilic inclusions in neutrophil granulocytes. In 
vitro functional studies (Born’s method) showed normal platelet aggregation after stimulation with 
ADP, collagen, and ristocetin. At re-evaluation, his 52-years-old mother had 30 x109/L platelets, no 
bleeding diathesis, and a history of bilateral hearing loss since the age of 40. Also the proband’s 
aunt (age 59 years) had thrombocytopenia without history of bleeding. Both proband’s relatives 
presented giant platelets and Döhle-like inclusions. The search for extra-hematological 
manifestations revealed severe bilateral sensorineural hearing loss (intermediate and high 
frequencies) in both the adult family members and bilateral cataract in the proband’s aunt. No other 
complications were found, in particular none of the affected subjects presented significant 
proteinuria.   
 
Family 2. The proband (II-1; Table 1 and Fig. 2) was a 44-year-old male referred for 
thrombocytopenia (platelet count 25 x109/L) discovered at the age of 3 years when he underwent 
tonsillectomy complicated by prolonged bleeding. He presented with easy bruising, recurrent 
epistaxis, and bleeding after tooth extractions despite prophylaxis with platelet transfusions. He also 
had severe bilateral sensorineural hearing loss, with onset at the age of 7 years and a rapidly 
progressive evolution to complete deafness. At the age of 12 years he was diagnosed as having 
immune thrombocytopenia and received steroids for two years without any significant improvement 
of the platelet count. When he was 17-years-old, the diagnosis of immune thrombocytopenia was 
confirmed and he underwent splenectomy without any increase in platelet count. Thereafter, he 
received further courses of steroids, vincristine, and cyclophosphamide, with any improvements, 
until the age of 21 when he refused any further treatments. He had no familial history of 
thrombocytopenia or major bleeding episodes. Our laboratory work-up demonstrated giant platelets 
and typical Döhle-like bodies in neutrophil granulocytes at examination of peripheral blood smear. 
Flow cytometry showed normal expression of the glycoproteins Ib-IX-V, IIb-IIIa, and Ia-IIa on the 
platelet surface; in vitro aggregation studies were not performed because of the low platelet count. 
Screening for kidney function revealed relevant proteinuria (2.2 gr/24 hours) and normal serum 
creatinine, while ophthalmological evaluation returned normal results (Table 1).  
 
Family 3. The proband (I-2; Table 1) was a 33-year-old female referred for thrombocytopenia 
discovered for the first time at the age of 31 during her first pregnancy. Assessment of her medical 
history revealed easy bruising, menorrhagia, prolonged bleeding after minor wounds, and 
occasional epistaxis. The patient was also affected by type I von Willebrand disease which could 
contribute to bleeding tendency. She previously received a diagnosis of immune thrombocytopenia 
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and was treated with steroids and intravenous immunoglobulins without any responses. Assessment 
of family history revealed that her mother had a reduced platelet count diagnosed as immune 
thrombocytopenia; she received several courses of immunosuppressive treatments and splenectomy 
without any increases in platelet count, and she died because of severe bleeding. At our evaluation, 
platelet count was 85 x109/L, as assessed by phase contrast microscopy. Examination of peripheral 
blood smears showed giant platelets and typical Döhle-like inclusion bodies. In vitro aggregation 
studies revealed a moderately reduced response to all tested agonists, including ADP, epinephrine, 
collagen and ristocetin. Flow cytometry showed that while glycoprotein IIb-IIIa expression was 
increased compared to control, levels of Ib-IX were moderately reduced. The proband’s two-year-
old son also had thrombocytopenia (96 x109/L), giant platelets and Döhle-like inclusions. The 
search for kidney damage and hearing loss returned normal findings in both the proband and her 
son, while ophthalmologic evaluation was normal in the proband (her son had no ophthalmologic 
evaluation done so far).  
 
Family 4. The proband (II-1; Table 1) was an 8-year-old girl referred for mild thrombocytopenia 
(platelet count 123 x109/L) and increased bleeding after adenoidectomy. Medical history revealed 
recurrent episodes of epistaxis and excessive bleeding after the loss of one milk tooth. She 
underwent surgical correction of umbilical hernia without complications. Examination of blood 
smears revealed giant platelets and Döhle-like inclusion bodies. In vitro functional studies (Born’s 
method) showed normal platelet aggregation after stimulation with collagen, ristocetin, and ADP. 
Flow cytometry demonstrated normal platelet expression of glycoproteins IIb-IIIa, Ib-alpha, and Ib-
beta. The proband’s 43-year-old father also had thrombocytopenia (platelet count 116 x109/L) 
discovered for the first time at the age of 28 when he was diagnosed as having immune 
thrombocytopenia. He presented with easy bruising and mild gum bleeding. He also had giant 
platelets and Döhle-like bodies at evaluation of blood smears.  Except for a mild, clinically 
unnoticed, bilateral hearing loss limited to the higher frequencies (30 dB at 8 kHz) in the proband’s 
father, no extra-hematological manifestations of the MYH9-RD were observed in both the family 
members. 
 
Family 5. The proband was a 20-year old female referred for a lifelong history of 
thrombocytopenia. She suffered from easy bruising and epistaxis. During infancy, she received a 
diagnosis of immune thrombocytopenia and was treated with steroids without any response. At our 
evaluation, platelet count was 65 x109/L, as assessed by phase contrast microscopy. Examination of 
her peripheral blood smears showed giant platelets and Döhle-like inclusions. Flow cytometry 
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showed normal expression of the glycoproteins Ib-IX-V, IIb-IIIa, and Ia-IIa on the platelet surface. 
The search for kidney damage, hearing loss, and cataracts returned normal results.  
 
Immunofluorescence studies 
 
Immunofluorescence analysis for myosin-9 localization in neutrophils was performed on peripheral 
blood smears using the NMG2 mouse monoclonal antibody. Goat anti-mouse conjugated with 
Alexa Fluor 488 (Invitrogen, Milan, Italy) was used for secondary detection, as previously 
described [11]. 
 
Mutational analysis of MYH9 
 
Probands of families 1 and 2 were screened for mutations in exons 1 and 16 of the MYH9 gene 
whereas probands of family 3, 4 and 5 were analyzed first for the “hot” exons 1, 16, 38 and 40 and 
then for the exons 10, 24, 25, 26, and 30. Proband of family 3 was also screened for the remaining 
MYH9 exons. The coding exons and the respective exon-intron boundaries of MYH9 were amplified 
by PCR and the products were sequenced using an ABI PRISM BigDye Terminator Cycle 
Sequencing Ready Reaction Kit and an ABI 310 Genetic Analyzer (Applied Biosystems, Foster 
City, CA) as previously described [11, 12]. 
 
Bioinformatics 
 
The structure with the closest sequence homology with MYH9 was identified by a Blast search of 
the PDB database (http://blast.ncbi.nlm.nih.gov/Blast.cgi). The query sequence was aligned to that 
of the template by the clustalx software. The model was built using the expasy Swiss-Model 
repository used in automated mode (http://swissmodel.expasy.org/repository/).  
 
 
RESULTS AND DISCUSSION 
 
In the probands, the diagnosis of MYH9-RD was suspected because of the finding of giant platelets 
and typical Döhle-like basophilic inclusions in neutrophils, which was associated with the extra-
hematological manifestations of the disease in some cases (Table 1). In members of families 1-3 
and 5, the immunofluorescence analysis revealed typical myosin-9 aggregates in neutrophil 
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granulocytes, thus confirming the diagnosis [3, 11]. In families 1 and 2, the staining pattern was 
characterized by numerous aggregates of small size (<0.5 µm) (Fig 2C), suggesting a mutation 
affecting the motor domain of myosin-9 [2, 4]. In families 3 and 5, patients’ neutrophils had one to 
four large (2-5 µm) inclusions, often together with other small aggregates, as typically observed in 
subjects with alterations of the tail domain [2]. The immuofluorescence analysis was not performed 
in the members of family 4. 
 
Mutational screening revealed five novel heterozygous mutations (Table 1). In the proband of 
families 1 and 2, we identified the c.101T>G (p.Val34Gly) and the c.2104C>A (p.Arg702Ser) 
missense mutations of exons 1 and 16, respectively (Fig. 1 and 2). In families 3 and 4 we detected 
two in frame alterations, the c.2539_2559dup (p.Met847_Glu853dup) in exon 20 and the 
c.3142_3162del (p.Lys1048_Glu1054del) in exon 24 (Fig. 3). In the last proband, the c.4338G>T 
mutation in exon 30 lead to the p.Asp1447Tyr substitution. Whereas the mutations in pedigrees 1, 
3, and 4 segregated within the respective families, p.Arg702Ser identified in family 2 was likely to 
have occurred as de novo event, as the proband’s parents did not present any feature of the disease. 
However, their DNA samples were not available to confirm this hypothesis. Familial history was 
not available for the proband of family 5. The five mutations were not reported in the SNP 
databases (http://www.ncbi.nlm.nih.gov/SNP). 
 
The amino acid alignment of the 13 human myosin heavy chains of class II showed conservation of 
valine 34 in all but one (MYH10) protein (Fig. 1C). Valine 34 is also conserved among the MYH9 
orthologs (Canis lupus familiaris, Bos Taurus, Mus musculus, Rattus norvegicus, Gallus gallus, and 
Danio rerio; at http://www.ncbi.nlm.nih.gov/homologene; data not shown), suggesting that it exerts 
a fundamental role in the structure and function of the class II myosins. In fact, inspection of the 
crystal structure (PDB entry name 1br2 for chicken smooth muscle myosin) shows that the mutation 
of valine 34 to a glycine affects an N-terminal residue of a small domain formed by two short beta-
hairpins that pack against each other after relative rotation of an approximately 90 degree angle 
(Fig. 1D). The valine is in the interface and is buried from the solvent (exposed surface area of 1 
Å2). It is surrounded by other hydrophobic residues (Ile49, Val57, Val59, Leu61, Leu70 and Ile75). 
The identified mutation is therefore likely to have a structural role and destabilize the protein fold. 
 
The arginine at residue 702 is also a conserved amino acid, as previously reported for other two 
mutations hitting the same residue, p.Arg702Cys and p.Arg702His [2, 7]. This residue is exposed 
on the protein surface (exposed surface area of 122 Å2). The side chain points towards the spatially 
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nearby Glu94 with which Arg702 can form a salt bridge (Fig. 2D). Mutation of the residue in the 
shorter serine and cysteine or in the pH sensitive histidine could abolish this interaction and lead to 
destabilization of the structure. As arginine 702, even asparagine at residue 1447 of the coiled-coil 
tail is a conserved amino acid, which was previously found to be hit by mutations p.Asp1447His 
and p.Asp1447Val in a few MYH9-RD patients [11, 13].  
 
Regarding the two in frame mutations, it is interesting to note that other in frame alterations, two 
deletions (c.3164_3205del/p.Gly1055_Gln1068del and c.3195_3215del/p.Glu1066_Ala1072del) 
and one duplication (c.3195_3215dup/p.Glu1066_Ala1072dup) have previously been identified in 
exon 24 [14, 15]. Such rearrangements are likely to derive from unequal homologous recombination 
between non-allelic regions repetitive elements, as hypothesized for c.3164_3205del and 
c.3195_3215del/dup. Indeed, exon 24 is rich of repetitive elements, including two AGCTGGAG 
units that are likely to be responsible for c.3142_3162del (Fig. 3A). Similarly, the duplicated stretch 
of 21 bp in exon 20 is flanked by the AGGAGGAGGAG repetitive sequence (Fig. 3B). 
Interestingly, all these rearrangements remove or add 7 or 14 residues of the α-coiled coil rod 
domain of the myosin, which consists of a 28 amino acid unit repeated 40 times [16]. This unit is 
subdivided itself in four heptad repeat motifs that are typical of the coiled-coil structure. More 
precisely, the p.Met847_Glu853dup and p.Lys1048_Glu1054 mutations hit the second and the 
eighth units and are likely to cause a significant dominant negative effect by interfering with the 
correct dimerization of myosin-9 and its assembly in filaments. 
 
We and others have recently reported genotype-phenotype correlations in MYH9-RD [9, 17]. 
Patients with mutations affecting the globular head domain of myosin-9 have lower platelet counts 
and higher prevalence and severity of extra-hematological manifestations than the subjects with 
mutations in the tail domain. Consistent with these studies, the patients from family 1 presented 
with moderate to severe thrombocytopenia associated with sensorineural hearing loss and/or 
bilateral cataracts in both the adult members. Similarly, the patient of family 2 presented with very 
low platelet count associated with early-onset, profound deafness and proteinuric nephropathy. In 
particular, these findings confirm the previous observation that the arginine 702 substitution 
invariably affects the hearing and kidney function since the juvenile age [8-10]. On the contrary, 
patients from families 3-5 had slight to moderate thrombocytopenia and no extra-hematological 
manifestations, with the exception of a very mild, clinically unnoticed sensorineural hearing defect 
in the adult member of family 4. 
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Despite the history of severe sensorineural deafness since the pediatric age, in the proband of family 
2 the MYH9-RD was suspected only after the administration of several unnecessary treatments, 
including splenectomy, as a result of a wrong diagnosis of immune thrombocytopenia. As 
mentioned above, the mutation in this family is likely to have occurred as a de novo event, as both 
the patient’s parents were healthy and had normal platelet counts. The lack of a familial history 
could have contributed to the misdiagnosis. Also the proband of family 3 received a wrong 
diagnosis of immune thrombocytopenia and undue treatments, despite her mother had a history of 
thrombocytopenia unresponsive to immunosuppressive drugs and splenectomy. These case reports 
emphasize the importance of considering the associated clinical manifestations typical of syndromic 
inherited thrombocytopenias, as well as of the examination of blood smears to search for giant 
platelets and Döhle-like leukocyte inclusions, in the evaluation of patients with thrombocytopenia 
[18]. Moreover, although in many cases the genetic origin of thrombocytopenia can be easily 
suspected for the presence of a low platelet count in one of the parents, it appears important the 
awareness that about 35% of MYH9-RD patients are sporadic cases, and, therefore, present with no 
familial history of thrombocytopenia [2].  
 
In conclusion, we reported five novel MYH9 mutations that extend the spectrum of alterations 
causing MYH9-RD. The phenotype of the reported patients is consistent with the current model of 
genotype-phenotype correlations.  
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Figure legends 
 
Fig. 1. Identification of the p.Val34Gly mutation in family 1. A) Family pedigree; B) Direct 
sequencing of PCR products of exon 1 demonstrates two overlapping peaks of the heterozygous 
c.101T>G mutation; C) Alignment of all human muscle and non muscle myosins of class II with 
the conserved residues boxed. MYH1 (NM_005963), MYH4 (NM_017533), MYH2 (NM_017534), 
MYH8 (NM_002472), MYH3 (NM_002470), MYH13 (NM_003802), MYH7 (MN_000257), 
MYH6 (NM_002471), MYH9 (AB191263), MYH10 (NM_005964), MYH11 (NM_002474), and 
MYH14 (AY165122); D) Ribbon structure of the smooth muscle myosin motor domain (1br2). The 
side chain of Val34 (in the pdb numbering Val37) is indicated in red. The side chains of 
surrounding hydrophobic residues (I49, V57, V59, L61, L70 and I75) are shown in blue.  
 
Fig. 2. Identification of the p.Arg702Ser mutation in family 2. A) Family pedigree; B) Direct 
sequencing of PCR products of exon 16 with overlapping peaks of the heterozygous c.2104C>A 
mutation; C) Immunofluorescence analysis showing myosin-9 small aggregates in the patient 
neutrophils; D) Effect of the mutation on the structure (1br2). The ribbon representation is shown 
with the same orientation as before. The side chain of Arg702 is shown in blue, Glu94 is shown in 
red. 
 
Fig. 3. Schematic representation of the in-frame mutations identified in families 3 and 4. A) 
Nucleotide sequence of exon 20 (capital letters) and its flanking intronic regions where the 
c.2539_2559dup mutation is indicated. The repetitive AGGAGGAGGAG elements that are likely 
to be involved in the rearrangements are boxed. B) Nucleotide sequence of exon 24 (capital letter), 
where three deletions and one duplication (c.3142_3162del, c.3164_3205del, and 
c.3195_3215del/dup) so far identified are indicated. The repetitive that are elements to be likely 
involved in the rearrangements are boxed or dotted.  
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Table 1. Main clinical and molecular features of nine MYH9-RD patients with five novel MYH9 mutations.  
Family/
Patient 
Age/ 
Gender 
Platelet count 
(x109/L)a 
Giant platelets/ 
leukocyte 
inclusionsb 
Bleeding timec Bleeding diathesis Proteinuria
 / 
renal failure 
Sensorineural 
hearing lossd Cataract
e
 Mutationf 
 
1/I-1 
 
52 / F 30 yes / yes normal None no / no bilateral no 
 
1/I-2 
 
59 / F 40 yes / yes normal None no /no bilateral bilateral 
 
1/II-1 
 
11 / M 72 yes / yes normal None no / no no no 
c.101T>G 
(p.Val34Gly) 
2/II-1 44 / M 25 yes / yes increased 
 
Easy bruising, 
epistaxis, bleeding 
after teeth extraction 
 
yes / no bilateral no c.2104C>A (p.Arg702Ser) 
3/I-2 33 / F 85 yes / yes nd 
 
Easy bruising, 
menorrhagia, 
epistaxis 
 
no /no no no 
3/II-1 2 / M 96 yes / yes nd 
 
None no / no no nd 
c.2539_2559dup 
(p.Met847_ 
Glu853dup) 
4/I-1 43 / M 116 yes / yes increased 
 
Easy bruising, 
gum bleeding 
 
no / no 
 
bilateral 
(mild) 
 
no 
4/II-1 8 / F 123 yes / yes increased 
 
Epistaxis, bleeding 
after surgery and 
loss of one milk 
tooth 
 
no / no no no 
c.3142_3162del 
(p.Lys1048_ 
Glu1054del) 
5/I-1 20 /F 65 yes / yes nd 
 
Easy bruising, 
epistaxis 
 
no / no no no c.4339G>T (p.Asp1447Tyr) 
 
aAssessed by phase contrast microscopy. In MYH9-RD, the actual platelet count can be determined only by microscopic counting because automatic cell counters 
do not recognize giant platelets and therefore greatly underestimate platelet count (reference 1). bEvaluated by examination of peripheral blood smears. cEvaluated 
according to the Ivy method. dEvaluated by audiometric examination. eEvaluated by ophthalmological examination. fNucleotide A of the ATG translation initiation 
start site of the MYH9 cDNA (GenBank sequence NM_002473.3) is indicated as nucleotide +1. nd, not determined. 
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